Medicines: Pemigatinib

FIGHT-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma

Pemigatinib – Mechanism of Action and Synthesis

Named Reactions in Organic Chemistry

The rapid growth of FGFR2 inhibitors: pemigatinib in FIGHT-202

The promise of pemigatinib for patients with FGFR1-rearranged MLN

VJHemOnc – Video Journal of Hematology & HemOnc

Final results from FIGHT-202: pemigatinib for patients with FGFR-mutated advanced cholangiocarcinoma

FIGHT-202: pemigatinib for FGFR2 altered CCA

The impact of the FDA approval of pemigatinib

VJHemOnc – Video Journal of Hematology & HemOnc

Therapeutic Management of Biliary Cancers: Integrating Precision Medicine With Targeted Strategies

PeerView Oncology

Insights into pemigatinib and the recent FDA approval of this agent

VJHemOnc – Video Journal of Hematology & HemOnc

Translational Dysequilibrium at the Bedside-Bench Interface

NCI Scientific Events and Resources

FDA approval of pemigatinib for R/R myeloid/lymphoid neoplasms: a major advance in the field

VJHemOnc – Video Journal of Hematology & HemOnc

FIGHT-202: pemigatinib in CCA

FIGHT-203 trial: pemigatinib in patients with MLNs with FGFR1 rearrangement

VJHemOnc – Video Journal of Hematology & HemOnc

FGFR2 Inhibitors in Advanced Cholangiocarcinoma

Targeted Oncology

Targeted therapies for cholangiocarcinoma in the second line setting

Arndt Vogel, MD, offers his opinion on pemigatinib in the management of cholangiocarcinoma

Implementing precision medicine for biliary tract cancer

Megan Murphy | Treatment

GCA

Promising future for cholangiocarcinoma diagnosis and treatment

Pharmacology of pemigatinib used for treatment of cholangiocarcinoma (New Drug 2020)

Ranjan Kumar Patel